Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.
Families will finally have an option to protect their newborns against respiratory syncytial virus, the leading cause of hospitalization among infants.
The FDA approved AstraZeneca and Sanofi’s Beyfortus this week, a monoclonal antibody that is administered as a single shot before or during an infant’s first RSV season.
RSV overwhelmed children’s hospitals last fall, triggering calls for the Biden administration to declare a public health emergency. Beyfortus, if widely adopted, promises to substantially reduce the burden of RSV on families and the health system.
The U.S. may soon have a second drug in its arsenal to help slow Alzheimer’s disease. Eli Lilly said this week that it expects the FDA to make a decision on donanemab by the end of the year.
And Johnson & Johnson this week joined the pharmaceutical industry’s campaign to take down Medicare’s new powers to slash drug prices. J&J is the third drugmaker to directly challenge the Biden administration in court.
The U.S. Chamber of Commerce and PhRMA, the pharmaceutical industry’s lobby group, have also filed lawsuits against the drug negotiations.
Feel free to send any tips, suggestions, story ideas and data to me at spencer.kimball@nbcuni.com.
